Keith Lamont Cummings Pliant Therapeutics, Inc. (PLRX) insider trading activity

Keith Lamont Cummings is Chief Financial Officer of PLIANT THERAPEUTICS, INC.. Currently has a direct ownership of 282,115 shares of PLRX, which is worth approximately $3.59 Million. The most recent transaction as insider was on Jul 10, 2024, when has been sold 10,911 shares (Common Stock) at a price of $11.56 per share, resulting in proceeds of $126,131. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 282K

0% 3M change

38.29% 12M change

Total Value Held $3.59 Million

Keith Lamont Cummings Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 10 2024	SELL Open market or private sale	$126,131 $11.56 p/Share	10,911 Reduced 3.72%	282,115 Common Stock
Jul 09 2024	BUY Grant, award, or other acquisition	-	21,313 Added 6.78%	293,026 Common Stock
May 02 2024	BUY Exercise of conversion of derivative security	$43,680 $2.08 p/Share	21,000 Added 7.17%	271,713 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	55,250 Added 18.11%	249,855 Common Stock
Jan 17 2024	SELL Open market or private sale	$168,526 $17.23 p/Share	9,781 Reduced 4.79%	194,605 Common Stock
Jul 17 2023	SELL Open market or private sale	$356,075 $18.01 p/Share	19,771 Reduced 8.84%	203,999 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	-	38,750 Added 14.76%	223,770 Common Stock
Jun 13 2023	BUY Exercise of conversion of derivative security	$63,960 $2.08 p/Share	30,750 Added 14.25%	185,020 Common Stock
Jun 09 2023	BUY Exercise of conversion of derivative security	$12,064 $2.08 p/Share	5,800 Added 3.62%	154,270 Common Stock
Mar 30 2023	SELL Open market or private sale	$264,139 $26.52 p/Share	9,960 Reduced 6.29%	148,470 Common Stock
Mar 29 2023	BUY Grant, award, or other acquisition	-	19,375 Added 10.9%	158,430 Common Stock
Jan 25 2023	BUY Grant, award, or other acquisition	-	54,000 Added 28.06%	138,424 Common Stock
Jan 23 2023	SELL Open market or private sale	$1,050,000 $35.0 p/Share	30,000 Reduced 26.22%	84,424 Common Stock
Jan 23 2023	BUY Exercise of conversion of derivative security	$124,500 $4.15 p/Share	30,000 Added 20.77%	114,424 Common Stock
Dec 22 2022	BUY Exercise of conversion of derivative security	$8,320 $2.08 p/Share	4,000 Added 4.52%	84,424 Common Stock
Dec 20 2022	SELL Open market or private sale	$184,181 $19.1 p/Share	9,643 Reduced 10.71%	80,424 Common Stock
Dec 19 2022	BUY Grant, award, or other acquisition	-	19,375 Added 17.7%	90,067 Common Stock
Sep 03 2021	BUY Exercise of conversion of derivative security	$41,600 $2.08 p/Share	20,000 Added 22.83%	67,621 Common Stock
Mar 05 2021	BUY Exercise of conversion of derivative security	$41,600 $2.08 p/Share	20,000 Added 29.58%	47,621 Common Stock
Dec 21 2020	BUY Exercise of conversion of derivative security	$9,360 $2.08 p/Share	4,500 Added 14.01%	27,621 Common Stock
Dec 01 2020	SELL Open market or private sale	$553,777 $29.56 p/Share	18,734 Reduced 44.76%	23,121 Common Stock
Dec 01 2020	BUY Exercise of conversion of derivative security	$77,746 $4.15 p/Share	18,734 Added 30.92%	41,855 Common Stock

KLC

Keith Lamont Cummings

Chief Financial Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PLRX shares.

Notify only if

Value

Insider Trading

Get notified when an Pliant Therapeutics, Inc. insider buys or sells PLRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to PLIANT THERAPEUTICS, INC.

Track Activities on PLRX

Account